表观遗传修饰与干细胞分化调控

干细胞具有自我更新和多种分化潜能的特性。干细胞向分化细胞的转变涉及到基因表达模式的改变,与自我更新有关的基因关闭．与细胞特化有关的基因激活。表观遗传调控机制,包括DNA甲基化、组蛋白修饰和微RNA（microRNA）介导的基因调控,在多个层面上控制发育过程中基因表达。近年研究表明,动态的表观遗传调控机制在干细胞自我更新和分化中起关键作用。     

表观遗传修饰在学习记忆中的研究进展

学习记忆是大脑的重要功能.记忆的形成涉及基因转录、新蛋白质合成和突触可塑性改变等一系列分子和细胞乃至神经环路的变化.近些年研究者逐渐发现各种表观遗传修饰,包括DNA甲基化、组蛋白修饰及RNA修饰在各种学习记忆类型、记忆阶段和突触可塑性中发挥了不同程度的作用.本文阐述了参与学习记忆的不同表观遗传调控因子,为进一步理解学习...     

表观遗传修饰与肿瘤

肿瘤的形成受遗传学修饰和表观遗传修饰的影响。长期以来人们一直认为基因突变参与肿瘤的形成,近年来越来越多的证据表明,表观遗传修饰在肿瘤进展中同样具有非常重要的作用。表观遗传调控可以影响基因转录活性而不涉及DNA序列的改变。本文介绍了肿瘤发生发展过程中出现的表观遗传修饰异常,以及通过干预表观遗传修饰治疗肿瘤的应用前景。     

表观遗传学与子宫内膜癌的研究进展

长期以来人们一直认为基因突变或缺失参与肿瘤的形成,近年来越来越多证据表明,表观遗传修饰在肿瘤进展中同样具有非常重要的作用。DNA甲基化、组蛋白修饰及microRNA表达调控等表观遗传机制是子宫内膜癌发生、发展的重要原因之一。表观遗传学的研究进展不仅有助于子宫内膜癌的早期诊断,对分子靶向治疗子宫内膜癌亦显示出良好的应用前景。     

表观遗传学与子宫内膜癌的研究进展

长期以来人们一直认为基因突变或缺失参与肿瘤的形成,近年来越来越多证据表明,表观遗传修饰在肿瘤进展中同样具有非常重要的作用。DNA甲基化、组蛋白修饰及micro RNA表达调控等表观遗传机制是子宫内膜癌发生、发展的重要原因之一。表观遗传学的研究进展不仅有助于子宫内膜癌的早期诊断,对分子靶向治疗子宫内膜癌亦显示出良好的应用前景。     

表观遗传修饰介导的植物胁迫记忆

植物因其固着生长的方式, 已经进化出各类特殊的机制来适应多变的外界环境。为提高自身的存活率, 植物进化出一类胁迫记忆机制, 以适应环境和保护自己。表观遗传修饰不仅能调控植物的正常生长发育, 而且参与植物对各种非生物或生物胁迫的响应。近年的研究表明, 表观遗传修饰在植物胁迫记忆调控中也发挥重要作用。例如, DNA甲基化、组蛋白甲基化及乙酰化等表观遗传修饰参与并维持特定的胁迫记忆。该文主要对表观遗传修饰介导的植物胁迫记忆最新进展进行综述, 并展望未来的重点和热点研究方向。     

哺乳动物胚胎发生发育与表观遗传修饰

哺乳动物受精过程中染色体构象发生剧烈的变化.来自精子高度凝缩的染色质在卵母细胞胞质环境中解凝缩,与雌性染色质融合,发生基因组重编程共同构建合子基因组,激活胚胎基因组转录,获得发育的全能性,并进一步发育成完整的胚胎.表观遗传调节机制在这一过程中起重要作用,其中主要包括DNA甲基化、组蛋白甲基化、组蛋白乙酰化及组蛋白替代,这些修饰形式改变了染色体的空间构象以及与转录调节因子的结合模式,调控染色体的活性,进而调节胚胎的发生发育.     

铁死亡的表观遗传调控机制

铁死亡是一种新型的细胞程序性死亡方式,参与多种疾病的发生发展。对铁死亡调控机制的深入研究会帮助我们从新的角度去认识疾病的发生机制和探究潜在的药物干预靶点。因此,本文对铁死亡的表观遗传调控机制的最新研究进展进行了综述。研究发现,组蛋白的修饰如组蛋白甲基化、乙酰化和单泛素化等,能够通过激活或抑制铁死亡相关的溶质载体家族7成员11(recombinant solute carrier family 7 Member 11,SLC7A11)、谷胱甘肽过氧化物酶4(glutathione peroxidase 4,GPX4)等基因的转录进而调控铁死亡的发生。此外,DNA/RNA甲基化也影响着铁死亡的发生,如GPX4上游DNA甲基化的增加会导致脂质活性氧(reactive oxygen species,ROS)的积累从而促进细胞发生铁死亡。本文综述了近些年参与铁死亡调控的包括小分子RNA(microRNA)、长非编码RNA(long non-coding RNA,lncRNA)和环状RNA(circular RNA,circRNA)在内的非编码RNA的研究,发现非编码RNA也可以通过靶向调控谷胱甘肽(glutathione,GSH)合成、脂质ROS和GPX4活性等,在多种疾病尤其是肿瘤疾病的铁死亡过程中起举足轻重的作用。     

杂种优势形成的表观遗传学研究进展

杂种优势是一种复杂的生物学现象,在农业生产上得到了广泛的应用,但对其形成的遗传机理和分子基础尚不清楚。随着表观遗传学的深入研究,尤其是DNA甲基化、小分子RNA和组蛋白修饰等技术的发展,为杂种优势形成的分子基础提供了新的研究策略和技术手段。DNA甲基化、小分子RNA、组蛋白三者在杂交种中水平的改变与杂种优势有着一定关系,同时,三者之间相互作用调节基因表达影响杂种优势。本文简述了近年来表观遗传学在杂种优势形成中的作用和遗传机制等方面的研究进展,并且提出了目前存在的问题和下一步的研究方向。本综述将有助于从表观遗传学的角度认识杂种优势的形成机理,从而促进对杂种优势的表观遗传学基础的理解及其在植物杂交育种上的应用研究。     

表观遗传修饰介导的植物胁迫记忆

植物因其固着生长的方式, 已经进化出各类特殊的机制来适应多变的外界环境。为提高自身的存活率, 植物进化出一类胁迫记忆机制, 以适应环境和保护自己。表观遗传修饰不仅能调控植物的正常生长发育, 而且参与植物对各种非生物或生物胁迫的响应。近年的研究表明, 表观遗传修饰在植物胁迫记忆调控中也发挥重要作用。例如, DNA甲基化、组蛋白甲基化及乙酰化等表观遗传修饰参与并维持特定的胁迫记忆。该文主要对表观遗传修饰介导的植物胁迫记忆最新进展进行综述, 并展望未来的重点和热点研究方向。     

PI3K/Akt/mTOR信号通路及临床相关肿瘤抑制剂

哺乳动物雷帕霉素靶（mTOR）和蛋白激酶B（Akt/PKB）与肿瘤发生的密切关系已被广泛地认可.mTOR是一种丝/苏氨酸激酶,可以通过影响mRNA转录、代谢、自噬等方式调控细胞的生长.它既是PI3K的效应分子,也可以是PI3K的反馈调控因子.mTORC1 和mTORC2是mTOR的两种不同复合物. 对雷帕霉素敏感的mTORC1受到营养、生长因子、能量和应激4种因素的影响.生长因子通过PI3K/Akt信号通路调控mTORC1是最具特征性调节路径.而mTORC2最为人熟知的是作为Akt473磷酸化位点的上游激酶. 同样,Akt/PKB在细胞增殖分化、迁移生长过程中发挥着重要作用. 随着Thr308和Ser473两个位点激活,Akt/PKB也得以全面活化.因此,mTORC2-Akt-mTORC1的信号通路在肿瘤形成和生长中是可以存在的.目前临床肿瘤治疗中,PI3K/Akt/mTOR是重要的靶向治疗信号通路.然而,仅抑制mTORC1活性,不是所有的肿瘤都能得到预期控制.雷帕霉素虽然能抑制mTORC1,但也能反馈性地增加PI3K信号活跃度,从而影响治疗预后.近来发现的第二代抑制剂可以同时抑制mTORC1/2和PI3K活性,这种抑制剂被认为在肿瘤治疗上颇具前景.本综述着重阐述了PI3K/Akt/mTOR信号通路的传导、各因子之间的相互调控以及相关抑制剂的发展.     

RhoGDI2与PI3K/Akt/mTOR信号通路在肺癌细胞中的相关性研究

目的探讨肿瘤转移相关因子RhoGDI2与PI3K/Akt/mTOR信号通路在肺癌侵袭转移过程中的作用及相关机制。方法利用PI3K/Akt/mTOR信号通路上特异性的抑制剂,采用MTT法,伤口愈合实验及侵袭实验观察不同浓度药物对肺癌95D细胞生长侵袭转移能力的影响,通过Western Blot方法观察RhoGDI2蛋白水平的变化。结果PI3K抑制剂LY294002及mTOR抑制剂Rapamycin都能抑制肺癌细胞95D的侵袭转移能力,联合应用抑制作用更强。PI3K抑制剂LY294002处理组RhoGDI2蛋白的表达量增加,且随浓度增加RhoGDI2蛋白表达也增加。mTOR抑制剂Rapamycin组,在低浓度时增加RhoGDI2蛋白的表达,但增大Rapamycin的浓度,RhoGDI2蛋白的表达反而降低。低浓度LY294002组和Rapa-mycin组联合应用可以明显增加RhoGDI2蛋白的表达。结论PI3K/Akt/mTOR信号通路中Akt的活化与RhoGDI2密切相关,RhoGDI2可能直接或间接通过与Akt的相互作用参与调节肺癌的侵袭转移的过程。     

PI3K/AKT/mTOR信号通路及其在卵巢癌治疗中的应用

卵巢癌是女性生殖系统常见的恶性肿瘤,发病率居于妇科恶性肿瘤第三位,死亡率居于妇科恶性肿瘤之首。目前对卵巢癌的标准治疗包括肿瘤细胞减灭术及卡铂和紫杉醇的联合化疗。PI3K/AKT/mTOR信号通路在卵巢癌的细胞增殖、侵袭、细胞周期进展、血管生成及耐药中发挥重要作用,是卵巢癌中最常发生改变的细胞内途径。本文对PI3K/AKT/mTOR信号通路及其在卵巢癌增殖和进展中的影响、PI3K/AKT/mTOR信号通路抑制剂在卵巢癌中的治疗应用做简要综述。     

PI3K/Akt/mTOR信号通路与自噬及肿瘤的关系

自噬是一种以胞质内出现双层膜结构包裹长寿命蛋白和细胞器的自噬体为特征的细胞“自我消化”过程,在维持细胞内稳态、发育、肿瘤发生和感染中发挥重要作用。近来,诸多研究表明,自噬作为一把“双刃剑”,对肿瘤的发生发展既有促进作用,也有抑制作用。PI3K/Akt/mTOR通路由PI3激酶(PI3K)、蛋白激酶B（PKB/Akt）和哺乳动物类雷帕霉素靶蛋白（mTOR）3个作用分子组成,是一个中心的调节机构,对肿瘤细胞的生长与增殖有促进作用,同时对自噬进行抑制。本文就PI3K/Akt/mTOR通路与自噬及肿瘤发生发展的关系作一综述。     

Chamomile Essential Oil: Chemical Constituents and Antitumor Activity in MDA-MB-231 Cells through PI3K/Akt/mTOR Signaling Pathway

Chamomile essential oil (CEO) is extracted from chamomile and mainly used in aromatherapy. The chemical constituents and its antitumor activity on Triple-negative breast cancer (TNBC) was explored in the present study. Gas chromatography-mass spectrometry (GC/MS) was employed to analyze the chemical constituents of CEO. The cell viability, migration and invasion of TNBC cell MDA-MB-231 were measured using MTT, wound scratch and Transwell assay, respectively. The protein expression of PI3K/Akt/mTOR signaling pathway was determined by Western blot. CEO is rich in terpenoids (63.51 %), among which the identified terpenoids and their derivatives are mainly Caryophyllene (29.57 %), d-Cadinene (12.81 %), Caryophyllene oxide (14.51 %), etc. Three concentration of CEO (1, 1.5, 2 μg/mL) significantly inhibited the proliferation, migration and invasion of MDA-MB-231 cells with a dose dependent manner. Moreover, the phosphorylation of PI3K, Akt and mTOR was inhibited by CEO. The results revealed that there was abundant terpenoids in the CEO which account for 63.51 %. CEO significantly inhibited the proliferation, migration and invasion of MDA-MB-231 cells, exhibiting antitumor effect on TNBC. The antitumor effect of CEO might attribute to its inhibition on PI3K/Akt/mTOR signaling pathway. However, further study should be conducted in more TNBC cell lines and animal models to provide further evidence for TNBC treatment by CEO.     

Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors

This article describes the syntheses and SAR of a series of imidazolopyrimidine derivatives, which are evaluated as inhibitors of PI3-Kinase (PI3 K) and mTOR. These compounds were found to be ATP competitive with good tumor cell growth inhibition, and suppression of pathway specific biomakers such as phosphorylation of Akt at T308.     

Duvelisib attenuates bleomycin-induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease that seriously threatens the health of patients. The pathogenesis of IPF is still unclear, and there is a lack of effective therapeutic drugs. Myofibroblasts are the main effector cells of IPF, leading to excessive deposition of extracellular matrix (ECM) and promoting the progression of fibrosis. Inhibiting the excessive activation and relieving autophagy blockage of myofibroblasts is the key to treat IPF. PI3K/Akt/mTOR pathway plays a key regulatory role in promoting fibroblast activation and autophagy inhibition in lung fibrosis. Duvelisib is a PI3K inhibitor that can simultaneously inhibit the activities of PI3K-δ and PI3K-γ, and is mainly used for the treatment of relapsed/refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma tumour (SLL). In this study, we aimed to examine the effects of Duvelisib on pulmonary fibrosis. We used a mouse model of bleomycin-induced pulmonary fibrosis to evaluate the effects of Duvelisib on pulmonary fibrosis in vivo and further explored the potential pharmacological mechanisms of Duvelisib in lung fibroblasts in vitro. The in vivo experiments showed that Duvelisib significantly alleviated bleomycin-induced collagen deposition and improved pulmonary function. In vitro and in vivo pharmacological experiments showed that Duvelisib dose-dependently suppressed lung fibroblast activation and improved autophagy inhibition by inhibiting the phosphorylation of PI3K, Akt and mTOR. Our results indicate that Duvelisib can alleviate the severity of pulmonary fibrosis and provide potential drugs for the treatment of pulmonary fibrosis.     

PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes

Reduction in or dysfunction of glutamate transporter 1 (GLT1) is linked to several neuronal disorders such as stroke, Alzheimer’s disease, and amyotrophic lateral sclerosis. However, the detailed mechanism underlying GLT1 regulation has not been fully elucidated. In the present study, we first demonstrated the effects of mammalian target of rapamycin (mTOR) signaling on GLT1 regulation. We prepared astrocytes cultured in astrocyte-defined medium (ADM), which contains several growth factors including epidermal growth factor (EGF) and insulin. The levels of phosphorylated Akt (Ser473) and mTOR (Ser2448) increased, and GLT1 levels were increased in ADM-cultured astrocytes. Treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor or an Akt inhibitor suppressed the phosphorylation of Akt (Ser473) and mTOR (Ser2448) as well as decreased ADM-induced GLT1 upregulation. Treatment with the mTOR inhibitor rapamycin decreased GLT1 protein and mRNA levels. In contrast, rapamycin did not affect Akt (Ser473) phosphorylation. Our results suggest that mTOR is a downstream target of the PI3K/Akt pathway regulating GLT1 expression.